These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15986340)

  • 21. [The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis].
    Riente L
    Reumatismo; 2004; 56(1 Suppl 1):74-9. PubMed ID: 15201943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.
    Martinez-Taboada VM; Fontalba A; Blanco R; Fernández-Luna JL
    Arthritis Rheum; 2005 Jul; 52(7):2226-7. PubMed ID: 15986356
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome.
    Seitz M; Kamgang RK; Simon HU; Villiger PM
    Ann Rheum Dis; 2005 Dec; 64(12):1802-3. PubMed ID: 16284353
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.
    Bresnihan B
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii74-7. PubMed ID: 12379629
    [No Abstract]   [Full Text] [Related]  

  • 25. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 26. Refractory adult onset Still's disease successfully treated with anakinra.
    Vasques Godinho FM; Parreira Santos MJ; Canas da Silva J
    Ann Rheum Dis; 2005 Apr; 64(4):647-8. PubMed ID: 15374853
    [No Abstract]   [Full Text] [Related]  

  • 27. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis.
    Mirkinson LJ; Nagle D; Kadom N; Jones OY
    J Clin Rheumatol; 2006 Apr; 12(2):83-6. PubMed ID: 16601542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra.
    González-López MA; Martínez-Taboada VM; González-Vela MC; Fernández-Llaca H; Val-Bernal JF
    Br J Dermatol; 2008 May; 158(5):1146-8. PubMed ID: 18284383
    [No Abstract]   [Full Text] [Related]  

  • 29. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis--a pilot study.
    Omdal R; Gunnarsson R
    Rheumatol Int; 2005 Aug; 25(6):481-4. PubMed ID: 15071755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis.
    Bresnihan B; Cobby M
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii22-8. PubMed ID: 12817092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Kineret, Enbrel, Remicade and company. Recombinant drugs in rheumatoid arthritis].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2003; 32(5):376-83. PubMed ID: 14526457
    [No Abstract]   [Full Text] [Related]  

  • 32. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis.
    Kavanaugh A
    Adv Ther; 2006; 23(2):208-17. PubMed ID: 16751154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial response to interleukin 1 receptor antagonist in traps.
    Simon A; Bodar EJ; van der Hilst JC; van der Meer JW; Fiselier TJ; Cuppen MP; Drenth JP
    Am J Med; 2004 Aug; 117(3):208-10. PubMed ID: 15300976
    [No Abstract]   [Full Text] [Related]  

  • 34. Anakinra for arthritis.
    Pestell K
    Trends Pharmacol Sci; 2001 Aug; 22(8):401. PubMed ID: 11478998
    [No Abstract]   [Full Text] [Related]  

  • 35. Anakinra treatment of patients with rheumatoid arthritis.
    Calabrese LH
    Ann Pharmacother; 2002; 36(7-8):1204-9. PubMed ID: 12086555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using anakinra for adult rheumatoid arthritis.
    Kastanek L
    Nurse Pract; 2002 Apr; 27(4):62-5. PubMed ID: 11984420
    [No Abstract]   [Full Text] [Related]  

  • 37. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 38. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.
    Lovell DJ; Bowyer SL; Solinger AM
    Arthritis Rheum; 2005 Apr; 52(4):1283-6. PubMed ID: 15818707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism.
    Rynne M; Maclean C; Bybee A; McDermott MF; Emery P
    Ann Rheum Dis; 2006 Apr; 65(4):533-4. PubMed ID: 16531551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis.
    Kopp S; Alstergren P; Ernestam S; Nordahl S; Bratt J
    Scand J Rheumatol; 2006; 35(3):182-8. PubMed ID: 16766364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.